Senthil Damodaran, MD of MD Anderson talks about the common questions he receives about the Phase II study of copanlisib…
Browsing: Lymphoma
Senthil Damodaran, MD of MD Anderson explains the Phase II study of copanlisib in patients with tumors with PIK3CA mutations…
Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029,…
Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029,…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
Earn CME: https://www.naccme.com/program/20-hemcovid-2 In this webcast, Drs. Joseph R. Mikhael and John P. Leonard discuss challenges faced by US healthcare…
Earn CME: https://www.naccme.com/program/19-lm-15 In this webcast from the ‘New and Emerging Agents in MCL’ symposium during the 2019 Lymphoma &…
Earn CME: https://www.naccme.com/program/19-lm-14 In this webcast from the ‘Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic & Targeted Approaches’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Herbert Eradat, MD, MS @dgsomucla Associate Clinical Professor UCLE Lymphoma Program UCLA BMT & CAR-T Cell Program, David Geffen School…
Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the…
Earn CME: https://www.naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the…
Earn CME: https://www.naccme.com/program/7332 In this presentation from the ‘Confronting the Challenges of Peripheral T-Cell Lymphoma: Genomic Profiling and the Future…
ASH 2016 Page 5 Update on CAR-T Cell Therapy in Lymphoma
ASH 2016 Page 8 Leonard New Data for Mantel Cell and T-Cell Lymphoma Patients
ASH 2016 Page 7 Leonard Follicular Lymphoma Treatment Update
ASH 2016 Page 6 Leonard Update on Diffuse Large B Cell Lymphoma Treatments
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health shares details on the CLL14 trial…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health considers how CAR-T cell therapy may…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health explains the results of the umbralisib…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
What therapy should we use for DLBCL in 2016
Are vaccines dead in lymphoma and CLL
Are all DLBCL made equally
Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses New PI3K-Delta Inhibitor Umbralisib: Greater Then 50%…
David Andorsky MD Of US Oncology Research Discusses MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed…
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses Data On The ALLIANCE Trial. At…
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Low MRD. At…
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Its Effect On…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Where We Are In Our Understanding Of…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Whats Next In DLBCL. At MOASC on…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Next Steps In R-CHOP Studies. At MOASC…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Two Abstracts That Could Effect Clinicians. At…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Four Abstracts Presented At MOASC. At MOASC…
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Can A Rituximab Biosimilar Replace…
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses…
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Exciting Studies From ASH 2018…
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses ECHELON-2 Study. At The 60th…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope,…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope,…